Skip to main content
Equibles
IQV logo

IQV · Iqvia Holdings Inc.

Track IQV — free

Use IQV with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research IQV.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$265.12 -5.99 (-2.21%) At close · Nov 13
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$43.69B
Shares
164.80M
Volume · Nov 13 1.99M Avg daily vol (3M) 1.44M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$265.12 Open$271.72 Day$263.50–272.12 52W close$156.66–279.36 Avg vol 30d1.4M Short int3.0M · 1.8% of shares · 2.1d Short vol48% Last earningsOct 27, 2026 DataJan 2020–Nov 2026 Filing10-Q · Oct 27

Up next

Next earnings call
Feb 4, 2027 Est · unconfirmed · in 12 wks
Q3 2026 earnings call transcript
call held Oct 27, 2026
Play latest call

Latest documents

2026
Oct 27
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Quarterly report for FY2026 Q3

IQVIA reported revenue growth of $328 million, or 8.0%, in the third quarter of 2026. Research & Development Solutions backlog fell from $34.0 billion to $32.6 billion, with approximately $9.4 billion expected to convert within twelve months.

Revenue $4.43B ▲ 8.0% Net income $350M ▲ 5.7% Diluted EPS $2.10 ▲ 8.8%
Read from the MD&A section
Oct 27
Earnings call
Q3 2026 earnings call

IQVIA raised full year 26 revenue, adjusted EBITDA and adjusted diluted EPS guidance after third-quarter results exceeded the high end of guidance in each measure; R&D Solutions net new bookings were $3.2 billion, up 15% year over year.

Oct 27
Current report 8-K
Financial results

IQVIA Holdings Inc. reported third-quarter 2026 revenue of $4,428 million, up 8.0%, GAAP net income of $350 million and Adjusted Diluted Earnings per Share of $3.34, up 11.3%, and raised full-year 2026 guidance.

Sep 23
Current report 8-K
Entered into a material agreement, New debt or off-balance-sheet obligation

IQVIA Holdings Inc.’s wholly owned subsidiary IQVIA Inc. completed a $2,000,000,000 senior notes offering at 6.375% on September 23, 2026; proceeds will redeem 5.000% Senior Notes due 2026, repay revolving credit facility debt and cover fees.

Read from the first part of this long document
Sep 9
Current report 8-K
Other events AI summary on its way
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$17.31B
Trailing 12 months
Net income (TTM)
$1.39B
Trailing 12 months
Revenue growth YoY
+8.0%
Year over year
Operating margin
12.8%
Trailing 12 months
P / E (TTM)
32.3
Trailing earnings · reciprocal yield 3.1%
FCF yield
4.8%
TTM · current market cap
Return on invested capital
9.1%
Trailing 12 months
Net cash
−$13.64B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-2.7%
Year over year · fewer shares
Price change (1Y)
+18.6%
Trailing year
Short interest
1.8%
Latest settlement · 2.1 days to cover
View all 125 metrics

Quarterly results

Revenue Net income Net loss
▲2.3% $3.96B $437.00M '24 Q4* ▲2.5% $3.83B $249.00M '25 Q1 ▲5.3% $4.02B $266.00M '25 Q2 ▲5.2% $4.10B $331.00M '25 Q3 ▲10.3% $4.36B $514.00M '25 Q4* ▲8.4% $4.15B $274.00M '26 Q1 ▲8.7% $4.37B $256.00M '26 Q2 LATEST ▲8% $4.43B $350.00M '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

AI Brief

Q2 FY26 earnings call · Jul 28, 2026
Q2 FY26

TL;DR. IQVIA's Q2 2026 results exceeded the high end of guidance across revenue, adjusted EBITDA, and adjusted EPS, driven by accelerating organic growth, record R&D bookings of $3.15B (1.22x book-to-bill), and strong free cash flow, prompting the company to raise full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted EPS.

Bullish
  • + Organic growth accelerated to 6% year-over-year, roughly three times the prior-year rate.
  • + Free cash flow grew 23.3% year-over-year on strong operating cash flow.
  • + EBP funding of $35B in Q2 was more than double the prior-year quarter, supporting sustained R&D demand.
Bearish
  • − Foreign exchange is now only a ~20 bps tailwind vs. ~100 bps previously assumed, dragging reported growth.
  • − Pass-through revenue growth remains a non-operational margin headwind.
  • − Full-year 2026 adjusted EBITDA margin guidance reconfirmed as flat at ~23.2%, despite operational productivity gains.
  • − Net leverage ratio remains elevated at 3.59x trailing twelve-month adjusted EBITDA.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Moderate
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +26%
above
Price vs 50-day avg −1%
below
RSI (14) 46
neutral
MACD trend Negative
52-week position 88%
near high
Momentum
relative strength
Very Strong
1-month return −1%
trailing
6-month return +64%
trailing
YTD return +18%
this year
Relative strength +63%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $267 › 200d $211 — 50d above 200d
Institutional flow Accumulating
1,071 of 1,098 funds reported for Sep 30 · net +339.1K sh shares · +165 new
Insider flow Distributing
Net -$1.9M over 90 days · 100% sells
Short interest Rising
1.85% of shares out · ▲ +1.7% MoM · 2.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
1,098 holders — mid 3-yr range
Squeeze score 52
elevated · 0–100
Fundamentals
Strong
Revenue growth +42%
Y/Y
EPS growth +5%
Y/Y
Valuation P/E 32.3
below peers
Buyback $2.8B
remaining
Balance sheet $13.7B
net debt
Quant / Vol
risk profile
Moderate
Volatility 41%
annualized · 1-yr
Max drawdown −36%
past year
ATR 3.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 7 of last 8
Latest guidance · from the Earnings Call filed Jul 28, 2026
Adjusted diluted EPS · full year Non-GAAP $12.80 – $13.00
Previous outlook earlier release · from the 8-K filed May 5, 2026

Still-open targets the latest release did not restate under the same label.

Revenue · full-year 2026 $17.15B – $17.35B
Prior guidance period ended · from the Earnings Call filed May 5, 2026
Adjusted EBITDA · Q2 $955M – $975M
Guided vs delivered · last 8 settled
Revenue full-year 2025
guided $16.15B – $16.25B
$16.31B Beat +0.7%
Full-year revenue full-year 2024
guided $15.33B – $15.58B
$15.41B In line
Revenue full-year 2023
guided $14.89B – $14.92B
$14.98B Beat +0.5%
Revenue fourth quarter of 2023
guided $3.77B – $3.8B
$3.87B Beat +2.2%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+26% Bullish
Price vs 50-day avg
−1% Neutral
RSI (14)
46 Neutral
MACD trend
Negative Bearish
52-week position
88% Bullish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $267 › 200d $211 — 50d above 200d
Institutional flow Accumulating
1,071 of 1,098 funds reported for Sep 30 · net +339.1K sh shares · +165 new
Insider flow Distributing
Net -$1.9M over 90 days · 100% sells
Short interest Rising
1.85% of shares out · ▲ +1.7% MoM · 2.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
1,098 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $157 Now $265 · 88% Range high $279
vs 200-day avg +26% vs 50-day avg -1%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cost of revenues, exclusive of depreciation and amortization (% of revenues) 67.1% Three Months Ended June 30, 2026 filing —
Depreciation and amortization (% of revenues) 6.7% Three Months Ended June 30, 2026 filing —
Selling, general and administrative expenses (% of revenues) 13.1% Three Months Ended June 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Diagnostics & Research — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
IQV
Iqvia Holdings Inc.
this stock
$43.69B +17.6% +41.6% 32.3 1.8%
TMO
Thermo Fisher Scientific Inc.
 $259.44B +20.8% +14.5% 36.9 1.3%
DHR
Danaher Corp
 $163.94B +1.8% +8.5% 38.1 1.2%
IDXX
Idexx Laboratories Inc
 $55.48B +4.1% +10.4% 47.5 3.0%
A
Agilent Technologies, Inc.
 $49.04B +27.8% +6.4% 34.2 1.7%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
1,217
% held
95.8%
Reported
1,071 of 1,098
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
852
View
Short & Settlement
Short Interest Rising
Shares short
3.0M
Days to cover
2.1d
Change
+49.8K sh
View
Short Volume
Short vol %
48%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
81
Value
$21.0K
As of
Oct 9, 2026
View
Off-Exchange
Off-exchange %
47.5%
Week of
Oct 5, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$1.9M
Buyers / Sellers
0 / 2
Buyers Sellers
View
Congressional Trades Sell
Member
Kevin Hern
Amount
$15.0K–$50.0K
Traded
Sep 14, 2026
View
Financials
Financials
Revenue (FY)
$16.3B
Net income (FY)
$1.4B
EPS diluted
$7.84
View
Buybacks
Authorized
$15.7B
Remaining
$2.8B
Spent Remaining
View
Filings
SEC Filings
Latest
8-K
Filed
Oct 27, 2026
This year
22

IQVIA Holdings Inc. reported third-quarter 2026 revenue of $4,428 million, up 8.0%, GAAP net income of $350 million and Adjusted Diluted Earnings per Share of $3.34, up 11.3%, and raised full-year 2026 guidance.

View
Proposed Sales
Value
$1.2M
Shares
4.4K
Filed
Nov 9, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 1, 2026
Last webcast
Oct 27, 2026
View
Investor Relations
Latest news
IQVIA Reports Third-Quarter 2026…
Published
Oct 27, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
IQV -2.5% -0.7% +63.7% -0.8% +17.6%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -5.1% +0.5% +63.2% -0.7% +7.0%

Capital returns

Buyback program · as of Sep 30, 2026
Authorized
$15.72B
Spent (derived)
$12.91B
Remaining
$2.82B
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1478242 CUSIP 46266C105 13F (30d) 999 filings 923 filers Visit website Investor relations